Neuromodulating mice and men: Are there functional species differences in neurotransmitter concentration?

Neuroscience and Biobehavioral Reviews

Volumn 33, Issue 7, 2009, Pages 1037-1041

  Fitzgerald, Paul J ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acetylcholine; Dopamine; GABA; Glutamate; Macaque; Microdialysis; Norepinephrine; Prefrontal cortex; Rodent; Serotonin

Indexed keywords

4 AMINOBUTYRIC ACID; ACETYLCHOLINE; ASPARTIC ACID; DOPAMINE; DOPAMINE RECEPTOR; GLUCOSE; GLUTAMIC ACID; NORADRENALIN; PYRUVIC ACID; SEROTONIN;

AMINO ACID SEQUENCE; CEREBROSPINAL FLUID FLOW; CONCENTRATION RESPONSE; DOPAMINE RELEASE; DOWN REGULATION; HUMAN; LIFESPAN; MICRODIALYSIS; MOOD; NEUROMODULATION; NEUROTRANSMISSION; NONHUMAN; OCCIPITAL CORTEX; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; SEQUENCE HOMOLOGY; SPECIES DIFFERENCE; UPREGULATION;

ANIMALS; BRAIN; HUMANS; NEURONS; NEUROTRANSMITTER AGENTS; SPECIES SPECIFICITY; SYNAPTIC TRANSMISSION;

EID: 67649494347     PISSN: 01497634     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neubiorev.2009.04.003     Document Type: Review

References (66)

1. Parrot, et al. Microdialysis monitoring of catecholamines and excitatory amino acids in the rat and mouse brain: recent developments based on capillary electrophoresis with laser-induced fluorescence detection-a mini-review. Cell. Mol. Neurobiol. 23 (2003) 793-804
2. Saunders R.C., Kolachana B.S., and Weinberger D.R. Microdialysis in nonhuman primates. Curr. Protoc. Neurosci. (2001) (May, Chapter 7, Unit 7.3)
3. Helmy A., Carpenter K.L., and Hutchinson P.J. Microdialysis in the human brain and its potential role in the development and clinical assessment of drugs. Curr. Med. Chem. 14 (2007) 1525-1537
4. Chen K.C. Evidence on extracellular dopamine level in rat striatum: implications for the validity of quantitative microdialysis. J. Neurochem. 92 (2005) 46-58
5. Guiard B.P., Lanfumey L., and Gardier A.M. Microdialysis approach to study serotonin outflow in mice following selective serotonin reuptake inhibitors and substance P (neurokinin 1) receptor antagonist administration: a review. Curr. Drug Targets 7 (2006) 187-201
6. Musshoff F., Menting T., and Madea B. Postmortem serotonin (5-HT) concentrations in the cerebrospinal fluid of medicolegal cases. Forensic Sci. Int. 142 (2004) 211-219
7. Stenfors C., and Ross S.B. Changes in extracellular 5-HIAA concentrations as measured by in vivo microdialysis technique in relation to changes in 5-HT release. Psychopharmacology (Berl.) 172 (2004) 119-128
8. Lundquist, et al. Effect on [11C]DASB binding after tranylcypromine-induced increase in serotonin concentration: positron emission tomography studies in monkeys and rats. Synapse 61 (2007) 440-449
9. Hillered L., Vespa P.M., and Hovda D.A. Translational neurochemical research in acute human brain injury: the current status and potential future for cerebral microdialysis. J. Neurotrauma 22 (2005) 3-41
10. Davalos A., Shuaib A., and Wahlgren N.G. Neurotransmitters and pathophysiology of stroke: evidence for the release of glutamate and other transmitters/mediators in animals and humans. J. Stroke Cerebrovasc. Dis. 9 (2000) 2-8
11. Thomas P.M., Phillips J.P., and O'Connor W.T. Microdialysis of the lateral and medial temporal lobe during temporal lobe epilepsy surgery. Surg. Neurol. 63 (2005) 70-79
12. Hutchinson, et al. Increases in GABA concentrations during cerebral ischaemia: a microdialysis study of extracellular amino acids. J. Neurol. Neurosurg. Psychiatry 72 (2002) 99-105
13. Saunders R.C., Kolachana B.S., and Weinberger D.R. Local pharmacological manipulation of extracellular dopamine levels in the dorsolateral prefrontal cortex and caudate nucleus in the rhesus monkey: an in vivo microdialysis study. Exp. Brain Res. 98 (1994) 44-52
14. Kolachana B.S., Saunders R.C., and Weinberger D.R. An improved methodology for routine in vivo microdialysis in non-human primates. J. Neurosci. Methods 55 (1994) 1-6
15. Zhang, et al. Capillary hydrophilic interaction chromatography/mass spectrometry for simultaneous determination of multiple neurotransmitters in primate cerebral cortex. Rapid Commun. Mass Spectrom. 21 (2007) 3621-3628
16. Parrot, et al. Capillary electrophoresis combined with microdialysis in the human spinal cord: a new tool for monitoring rapid peroperative changes in amino acid neurotransmitters within the dorsal horn. Electrophoresis 25 (2004) 1511-1517
17. Boyd B.W., Witowski S.R., and Kennedy R.T. Trace-level amino acid analysis by capillary liquid chromatography and application to in vivo microdialysis sampling with 10-s temporal resolution. Anal. Chem. 72 (2000) 865-871
18. Hernandez L.F., Segovia G., and Mora F. Effects of activation of NMDA and AMPA glutamate receptors on the extracellular concentrations of dopamine, acetylcholine, and GABA in striatum of the awake rat: a microdialysis study. Neurochem. Res. 28 (2003) 1819-1827
19. McKenzie, et al. Automated capillary liquid chromatography for simultaneous determination of neuroactive amines and amino acids. J. Chromatogr. A 962 (2002) 105-115
20. Yoshioka M., Matsumoto M., Togashi H., and Saito H. Effects of conditioned fear stress on 5-HT release in the rat prefrontal cortex. Pharmacol. Biochem. Behav. 51 (1995) 515-519
21. Isogawa, et al. Effect of corticotropin releasing factor receptor 1 antagonist on extracellular norepinephrine, dopamine and serotonin in hippocampus and prefrontal cortex of rats in vivo. Neuropeptides 34 (2000) 234-239
22. Koch S., Perry K.W., and Bymaster F.P. Brain region and dose effects of an olanzapine/fluoxetine combination on extracellular monoamine concentrations in the rat. Neuropharmacology 46 (2004) 232-242
23. Huang, et al. Asenapine increases dopamine, norepinephrine, and acetylcholine efflux in the rat medial prefrontal cortex and hippocampus. Neuropsychopharmacology 17 April (2008) (Epub ahead of print)
24. van der Plasse G., Meerkerk D.T., Lieben C.K., Blokland A., and Feenstra M.G. Lack of evidence for reduced prefrontal cortical serotonin and dopamine efflux after acute tryptophan depletion. Psychopharmacology (Berl.) 195 (2007) 377-385
25. Lapiz M.D., Bondi C.O., and Morilak D.A. Chronic treatment with desipramine improves cognitive performance of rats in an attentional set-shifting test. Neuropsychopharmacology 32 (2007) 1000-1010
26. Pan W.H., and Lai Y.J. Anesthetics decreased the microdialysis extraction fraction of norepinephrine but not dopamine in the medial prefrontal cortex. Synapse 21 (1995) 85-92
27. Finlay J.M., Zigmond M.J., and Abercrombie E.D. Increased dopamine and norepinephrine release in medial prefrontal cortex induced by acute and chronic stress: effects of diazepam. Neuroscience 64 (1995) 619-628
28. Yamamoto B.K., and Cooperman M.A. Differential effects of chronic antipsychotic drug treatment on extracellular glutamate and dopamine concentrations. J. Neurosci. 14 (1994) 4159-4166
29. Nakayama K., Katsu H., and Kitazumi K. Effect of distigmine bromide on the central cholinergic system. J. Psychopharmacol. May 30 (2008) (Epub ahead of print)
30. Prus A.J., Huang M., Li Z., Dai J., and Meltzer H.Y. The neurotensin analog NT69L enhances medial prefrontal cortical dopamine and acetylcholine efflux: potentiation of risperidone-, but not haloperidol-, induced dopamine efflux. Brain Res. 1184 (2007) 354-364
31. Li, et al. AC260584 (4-[3-(4-butylpiperidin-1-yl)-propyl]-7-fluoro-4H-benzo[1,4]oxazin-3-one), a selective muscarinic M1 receptor agonist, increases acetylcholine and dopamine release in rat medial prefrontal cortex and hippocampus. Eur. J. Pharmacol. 572 (2007) 129-137
32. Nair S.G., and Gudelsky G.A. 3,4-Methylenedioxymethamphetamine enhances the release of acetylcholine in the prefrontal cortex and dorsal hippocampus of the rat. Psychopharmacology (Berl.) 184 (2006) 182-189
33. de Groote L., Olivier B., and Westenberg H.G. Extracellular serotonin in the prefrontal cortex is limited through terminal 5-HT(1B) autoreceptors: a microdialysis study in knockout mice. Psychopharmacology (Berl.) 162 (2002) 419-424
34. Barnes Jr. E.M. Use-dependent regulation of GABAA receptors. Int. Rev. Neurobiol. 39 (1996) 53-76
35. Broadley K.J. Review of mechanisms involved in the apparent differential desensitization of beta1- and beta2-adrenoceptor-mediated functional responses. J. Auton. Pharmacol. 19 (1999) 335-345
36. Leysen J.E., Gommeren W., Janssen P.F., Van Gompel P., and Janssen P.A. Receptor interactions of dopamine and serotonin antagonists: binding in vitro and in vivo and receptor regulation. Psychopharmacol. Ser. 5 (1988) 12-26
37. Sanders-Bush E. Adaptive regulation of central serotonin receptors linked to phosphoinositide hydrolysis. Neuropsychopharmacology 3 (1990) 411-416
38. Garcia-Sainz J.A., Vazquez-Prado J., and del Carmen Medina L. Alpha 1-adrenoceptors: function and phosphorylation. Eur. J. Pharmacol. 389 (2000) 1-12
39. Muller C.P., and Carey R.J. Intracellular 5-HT 2C-receptor dephosphorylation: a new target for treating drug addiction. Trends Pharmacol. Sci. 27 (2006) 455-458
40. Meyer J.S., and Quenzer L.F. Psychopharmacology: Drugs, the Brain and Behavior. 1st ed. (2004), Sinauer Associates 555 pp
41. Johnson M.P., Baez M., Kursar J.D., and Nelson D.L. Species differences in 5-HT2A receptors: cloned pig and rhesus monkey 5-HT2A receptors reveal conserved transmembrane homology to the human rather than rat sequence. Biochim. Biophys. Acta 1236 (1995) 201-206
42. Dromey J.R., and Pfleger K.D. G protein coupled receptors as drug targets: the role of beta-arrestins. Endocr. Metab. Immune Disord. Drug Targets 8 (2008) 51-61
43. Grace A.A. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience 41 (1991) 1-24
44. Grace A.A. The tonic/phasic model of dopamine system regulation: its relevance for understanding how stimulant abuse can alter basal ganglia function. Drug Alcohol Depend. 37 (1995) 111-129
45. Goto Y., Otani S., and Grace A.A. The Yin and Yang of dopamine release: a new perspective. Neuropharmacology 53 (2007) 583-587
46. Grace A.A. The tonic/phasic model of dopamine system regulation and its implications for understanding alcohol and psychostimulant craving. Addiction 95 Suppl 2 (2000) S119-S128
47. Koyama Y., Jodo E., and Kayama Y. Sensory responsiveness of "broad-spike" neurons in the laterodorsal tegmental nucleus, locus coeruleus and dorsal raphe of awake rats: implications for cholinergic and monoaminergic neuron-specific responses. Neuroscience 63 (1994) 1021-1031
48. Waterhouse B.D., Devilbiss D., Seiple S., and Markowitz R. Sensorimotor-related discharge of simultaneously recorded, single neurons in the dorsal raphe nucleus of the awake, unrestrained rat. Brain Res. 1000 (2004) 183-191
49. Sakai K., and Crochet S. Differentiation of presumed serotonergic dorsal raphe neurons in relation to behavior and wake-sleep states. Neuroscience 104 (2001) 1141-1155
50. Hajos-Korcsok E. Rapid habituation of hippocampal serotonin and norepinephrine release and anxiety-related behaviors, but not plasma corticosterone levels, to repeated footshock stress in rats. Pharmacol. Biochem. Behav. 74 (2003) 609-616
51. Dazzi L., Seu E., Cherchi G., and Biggio G. Chronic administration of the SSRI fluvoxamine markedly and selectively reduces the sensitivity of cortical serotonergic neurons to footshock stress. Eur. Neuropsychopharmacol. 15 (2005) 283-290
52. Booij L., Van der Does A.J., and Riedel W.J. Monoamine depletion in psychiatric and healthy populations: review. Mol. Psychiatry 8 (2003) 951-973
53. Delgado P.L., and Moreno F.A. Role of norepinephrine in depression. J. Clin. Psychiatry 61 Suppl 1 (2000) 5-12
54. Murray G. Diurnal mood variation in depression: a signal of disturbed circadian function?. J. Affect. Disord. 102 (2007) 47-53
55. McCarley R.W. Neurobiology of REM and NREM sleep. Sleep Med. 8 (2007) 302-330
56. Stenberg D. Neuroanatomy and neurochemistry of sleep. Cell. Mol. Life Sci. 64 (2007) 1187-1204
57. Dalley J.W., Cardinal R.N., and Robbins T.W. Prefrontal executive and cognitive functions in rodents: neural and neurochemical substrates. Neurosci. Biobehav. Rev. 28 (2004) 771-784
58. Sackheim H.A., Roose S.P., and Burt T. Optimal length of antidepressant trials in late-life depression. J. Clin. Psychopharmacol. 25 4 Suppl 1 (2005) S34-S37
59. Posternak M.A., and Zimmerman M. Therapeutic effect of follow-up assessments on antidepressant and placebo response rates in antidepressant efficacy trials: meta-analysis. Br. J. Psychiatry 190 (2007) 287-292
60. Cryan J.F., Mombereau C., and Vassout A. The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice. Neurosci. Biobehav. Rev. 29 (2005) 571-625
61. Cryan J.F., Valentino R.J., and Lucki I. Assessing substrates underlying the behavioral effects of antidepressants using the modified rat forced swimming test. Neurosci. Biobehav. Rev. 29 (2005) 547-569
62. Dulawa S.C., and Hen R. Recent advances in animal models of chronic antidepressant effects: the novelty-induced hypophagia test. Neurosci. Biobehav. Rev. 29 (2005) 771-783
63. Kennedy, et al. Changes in regional brain glucose metabolism measured with positron emission tomography after paroxetine treatment of major depression. Am. J. Psychiatry 158 (2001) 899-905
64. Mayberg, et al. Regional metabolic effects of fluoxetine in major depression: serial changes and relationship to clinical response. Biol. Psychiatry 48 (2000) 830-843
65. Muly E.C., Maddox M., and Smith Y. Distribution of mGluR1alpha and mGluR5 immunolabeling in primate prefrontal cortex. J. Comp. Neurol. 467 (2003) 521-535
66. Marazziti, et al. Distribution of [3H]GR65630 binding in human brain postmortem. Neurochem. Res. 26 (2001) 187-190